BPC-157

ID: bpc157

Aliases: Body Protective Compound 157, BPC157

Type: compound

Route/form: published/preclinical routes vary; common oral/injection claims need route-specific evidence

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 10

Broad outcomes: Brain / mood / sleep, Gut / immune / inflammation, Muscle growth / performance / recovery, Skin / wound repair

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• tendon fibroblast migration/survival signaling
• FAK/paxillin and cytoskeletal remodeling in tendon cells
• angiogenesis and VEGF/eNOS-adjacent repair signaling
• wound repair and cytoprotection pathways
• nitric-oxide-system interaction in preclinical models

Optimization domains

• injury
• tendon
• ligament
• muscle
• wound healing
• GI
• angiogenesis
• soft tissue repair
• neuroprotection
• unapproved context

Research basis

• The strongest BPC-157 evidence is preclinical but broad: rat Achilles tendon studies show improved functional/biomechanical/microscopic healing, and explant/fibroblast work links the effect to tendon outgrowth, cell survival, migration, F-actin, and FAK/paxillin signaling.
• Review-level sources connect BPC-157 to angiogenesis/growth-factor repair concepts, wound healing, GI injury, tendon/ligament/muscle/bone models, and nitric-oxide-system interactions across animal models.
• A 2025 orthopedic sports-medicine systematic review is useful because it summarizes the real evidence map: many preclinical musculoskeletal studies, but only one clinical study located through mid-2024.

Limits, risks, and missing evidence

• The online use case is far ahead of the human evidence: there is no mature randomized human efficacy package for tendon, ligament, muscle, GI, or systemic recovery claims.
• Much of the positive literature comes from small animal models and a limited set of research groups, so reproducibility, dose translation, route translation, and publication-bias concerns are central.
• Subcutaneous/oral/intramuscular gray-market use should not be treated as equivalent to the routes, formulations, doses, and endpoints used across the preclinical literature.

Risk flags

• unapproved context
• preclinical only for most claims
• limited human data
• route translation uncertain
• dose translation uncertain
• sports ban context

Linked papers, labels, and reviews

1. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
   review / pubmed_bpc157_review_2025
   Recent review noting preclinical base and safety/regulatory uncertainty.
2. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
   review / pubmed_bpc157_orthopedic_systematic_review_2025
   Systematic review through June 2024; found 35 preclinical studies and 1 clinical study, so it supports broad musculoskeletal plausibility while emphasizing the thin human evidence base.
3. BPC 157 accelerates healing of transected rat Achilles tendon
   preclinical / pubmed_bpc157_achilles_2003
   Rat tendon model.
4. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
   preclinical / pubmed_bpc157_tendon_outgrowth_2010
   Rat Achilles tendon fibroblast/explant mechanism paper: BPC 157 increased tendon outgrowth, stress survival, migration, spreading, F-actin formation, and FAK/paxillin phosphorylation.
5. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
   review / pubmed_bpc157_musculoskeletal_soft_tissue_review_2019
   Critical musculoskeletal soft-tissue review covering tendon, ligament, and skeletal muscle models; explicitly notes that most evidence is small-rodent work and human efficacy is unconfirmed.
6. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing
   review / pubmed_bpc157_angiogenic_growth_factors_2018
   Mechanistic review linking BPC 157 to angiogenesis/growth-factor healing concepts across GI, tendon, ligament, muscle, and bone injury models.
7. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
   review / pubmed_bpc157_wound_healing_review_2021
   Wound-healing review spanning incisional/excisional wounds, burns, diabetic ulcers, fistula-like wounds, thrombosis/bleeding models, and ischemia-reperfusion framing, mostly from animal work.
8. Pentadecapeptide BPC 157 and the central nervous system
   review / pubmed_bpc157_cns_review_2021
   CNS-focused review covering rat stroke, spinal cord compression, catalepsy/dopamine-system models, and nitric-oxide-system interactions; useful for neuroprotection claims but not human cognitive evidence.
9. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle
   review / pubmed_bpc157_muscle_review_2022
   Muscle-axis review covering myotendinous junction, skeletal muscle disability models, smooth muscle, and cardiac-function models; mostly hypothesis-generating animal/preclinical synthesis.
10. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review
    review / pubmed_bpc157_literature_patent_review_2025
    Recent broad review of biological activities, mechanisms, probable toxicity, patent interest, online sale context, and lack of sufficient comprehensive clinical studies for standard medical approval.